This segment focuses on the research, development, production, and sale of single-use medical devices. R&D activities include the design and testing of vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized clinical collection kits. Technologies employed involve polymer science, sterilization techniques, and precision manufacturing. Therapeutic areas served include infusion therapy, blood collection, and general clinical procedures. The patient impact is significant, as these devices are essential for safe and effective medical treatments. Weigao Group holds a strong market position in China, with competitive advantages in manufacturing scale and product diversification. Future opportunities lie in expanding product lines and entering new markets. Regulatory compliance with Chinese and international standards is crucial. The company serves hospitals, blood stations, and distributors.

The Orthopaedic Products segment is dedicated to the research, development, manufacturing, and commercialization of orthopedic implants and instruments. R&D efforts focus on biomaterial science, implant design, and surgical techniques. Technologies include additive manufacturing (3D printing) for customized implants and advanced materials for enhanced biocompatibility and durability. Therapeutic areas include joint replacement, trauma, and spinal surgery. The patient impact is substantial, as these products improve mobility and quality of life for patients with musculoskeletal conditions. Weigao Group's market positioning benefits from its collaboration with Bright Laser Technologies (BLT) for additive manufacturing. Future opportunities include expanding the product portfolio and entering new markets. Regulatory compliance with Chinese and international standards is essential. The company serves hospitals and distributors.

This segment focuses on the development, production, and sale of instruments used in interventional procedures, including tumor and blood vessel interventions. R&D activities involve the design and testing of catheters, guidewires, and other specialized devices. Technologies include advanced materials science, imaging guidance, and minimally invasive techniques. Therapeutic areas include cardiology, oncology, and vascular surgery. The patient impact is significant, as these products enable less invasive and more effective treatments. Weigao Group's market positioning benefits from its focus on specialized medical devices. Future opportunities include expanding the product portfolio and entering new markets. Regulatory compliance with Chinese and international standards is crucial. The company serves hospitals and distributors.

This segment is dedicated to the production and sale of pharmaceutical packaging products, including prefilled syringes, plastic packing bags, and carton boxes. R&D activities focus on material science, packaging design, and sterilization techniques. Technologies include polymer processing, automated manufacturing, and quality control systems. Therapeutic areas include drug delivery and pharmaceutical storage. The patient impact is significant, as these products ensure the safety and efficacy of pharmaceutical products. Weigao Group's market positioning benefits from its integrated manufacturing capabilities and focus on quality. Future opportunities include expanding the product portfolio and entering new markets. Regulatory compliance with Chinese and international standards is essential. The company serves pharmaceutical companies and distributors.